Reprogramming the tumor microenvironment with biotechnology

Biomaterials Research

Table 1 Macrophage polarization with biomaterials

Type	Load	Delivery Materials	Therapy	Injection	Targeted protein	Ref
Toll-like Receptor	R848	Lignin nanoparticles	in vivo	intraperitoneal injection	CD206	[38]
	R848	CDNP-R848 with anti-PD-1	in vivo	intravenous injection	-	[36, 37]
	TLR7/8 agonist	Smac-TLR7/8 hydrogels with anti-PD-1	in vivo	peritumoral injection	CD86 andCD206	[29]
	TLR3	-	in vitro		CD86, CD206, and TIM-3	[40]
	TLR3	FP-NPs	in vivo	intravenous injection	-	[41]
	ES antigen	-	in vitro		CD11b	[44]
	Pam3, IFN-γ, and LPS	-	in vitro		CD14 and CD163	[43]
	-	Chitosan nanoparticle	in vivo	intravenous injection	-	[46]
CD47	CD47-blocking antibody (2C8)	-	in vivo	intravenous injection	CD47	[53]
	Anti-CD47 antibody	-	in vivo	intraperitoneal injection	CD47	[52]
	CD47-blocking antibody and CALR	Silica nanoparticle	in vivo	intratumoral injection	CD47	[57]
	Anti-CD47 and Imiquimod	IMD@HfDBP/αCD47 (nMOF)	in vivo	intratumoral injection	CD47	[54]
Albumin	TfR, SPARC	Albumin nanoparticle	in vivo	intravenous injection	-	[39]

ISSN: 2055-7124